Path of lease resistance? UP! Lmfao! CTD Holdings to Present at UK Annual Conference for NPC Patients, Families and Caregivers
Conference Brings Together European and International Families and Niemann-Pick Disease Type C Patient Advocates and Health Professionals
ALACHUA, FL -- (Marketwired) -- 09/22/17 -- CTD Holdings, Inc. (OTCQB: CTDH), a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of disease with unmet medical need, today announced that the company will present on its clinical and drug development program for the orphan drug, Trappsol® Cyclo™, at the Niemann-Pick UK 8th Interactive Workshop on Niemann-Pick Diseases and NPUK 24th Annual Family Conference. The conference will take place at the Mecure Haydock Hotel, Haydock, UK, from September 22 to 24.
CTD's presentations will focus on the Phase I and Phase I/II intravenous clinical trials of Trappsol® Cyclo™, its proprietary formulation of hydroxypropyl beta cyclodextrin, for the treatment of Niemann-Pick Disease Type C (NPC). Both the European Phase I/II and the U.S. Phase I trials are currently recruiting patients. The presentations will be made by Dr. Sharon Hrynkow, CTD's Senior Vice President for Medical Affairs and by Dr. Reena Sharma, Coordinating PI for the EU Trial and Principal Investigator at the Salford Royal NHS Trust Foundation, one of the EU trial sites. The Salford site announced dosing of the first patient in July 2017.
The conference brings together patients, families, caregivers and health professionals for the purposes of learning about advances in NPC clinical trials and providing opportunities for community learning, sharing and support.
